Company Name/Ticker Underwriter Price Range
Advanced Accelerator Applications
Jefferies & Co.
$13.00 - $15.00
5.4 mil
Jefferies & Co.
$12.00 - $14.00
4.6 mil
Asante Solutions
Leerink Partners
Cowen & Company
$13.00 - $15.00
3.5 mil
Avenue Financial Holdings
Keefe Bruyette Woods
Sandler O'Neill
$11.00 - $13.00
2.5 mil
Carbylan Therapeutics
Leerink Partners
JMP Securities
$12.00 - $14.00
5.8 mil
Chardan Capital Markets
Maxim Group LLC
$10.00 - $12.00
1.2 mil
Columbia Pipeline Partners LP
$19.00 - $21.00
40.0 mil
Easterly Government Properties
Raymond James
$14.00 - $16.00
12.0 mil
EyeGate Pharmaceuticals*
Aegis Capital Corp.
Chardan Capital Markets
$6.00 - $8.00
1.4 mil
RBC Capital Markets
Canaccord Genuity
$13.00 - $15.00
4.0 mil
Inotek Pharmaceuticals
Cowen & Company
Piper Jaffray
$13.00 - $15.00
4.6 mil
Inovalon Holdings
Goldman Sachs
Morgan Stanley
$21.00 - $24.00
22.2 mil
Nexvet Biopharma
BofA Merrill Lynch
Cowen & Company
$13.00 - $16.00
4.0 mil
Sol-Wind Renewable Power LP
UBS Investment Bank
$19.00 - $21.00
8.7 mil

EyeGate Pharmaceuticals - *Revised terms on 11/20/14. Previously planned to offer 1.9mm shares at $12-$14.
Check-Cap - *Offering units that consist of one ordinary share and one half of a warrant to purchase one share.
Please note our calendar only lists IPOs scheduled for the coming week. For a more in-depth calendar, please inquire about our institutional research service.
IPOs For Everyone Obtain Investor PacketAccess Your AccountInvest Online Today
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The Renaissance International IPO Index® (IPOXUS) is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO", the Renaissance International IPO ETF, symbol "IPOS" (the “ETFs”), and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the “Funds”) invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.